- Home
- TLPH vs KZIA Comparison
TLPH vs KZIA Comparison
Compare TLPH & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- KZIA
- Stock Information
- Founded
- TLPH 2005
- KZIA 1994
- Country
- TLPH United States
- KZIA Australia
- Employees
- TLPH N/A
- KZIA N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- KZIA Health Care
- Exchange
- TLPH Nasdaq
- KZIA Nasdaq
- Market Cap
- TLPH 13.4M
- KZIA 12.6M
- IPO Year
- TLPH 2011
- KZIA 1999
- Fundamental
- Price
- TLPH $0.79
- KZIA $0.41
- Analyst Decision
- TLPH Strong Buy
- KZIA Strong Buy
- Analyst Count
- TLPH 2
- KZIA 1
- Target Price
- TLPH $4.50
- KZIA $2.00
- AVG Volume (30 Days)
- TLPH 71.4K
- KZIA 553.5K
- Earning Date
- TLPH 11-06-2024
- KZIA 10-22-2024
- Dividend Yield
- TLPH N/A
- KZIA N/A
- EPS Growth
- TLPH N/A
- KZIA N/A
- EPS
- TLPH N/A
- KZIA N/A
- Revenue
- TLPH $398,000.00
- KZIA $382.00
- Revenue This Year
- TLPH N/A
- KZIA $4,053,954.00
- Revenue Next Year
- TLPH N/A
- KZIA N/A
- P/E Ratio
- TLPH N/A
- KZIA N/A
- Revenue Growth
- TLPH 57.31
- KZIA N/A
- 52 Week Low
- TLPH $0.43
- KZIA $0.19
- 52 Week High
- TLPH $1.61
- KZIA $1.58
- Technical
- Relative Strength Index (RSI)
- TLPH 40.28
- KZIA 53.72
- Support Level
- TLPH $0.76
- KZIA $0.38
- Resistance Level
- TLPH $0.83
- KZIA $0.46
- Average True Range (ATR)
- TLPH 0.08
- KZIA 0.03
- MACD
- TLPH -0.00
- KZIA 0.00
- Stochastic Oscillator
- TLPH 32.00
- KZIA 48.45
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.